Larimar Therapeutics Corporate Presentation July 2021 1 Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the "C

1Exhibit 99.1 Larimar Therapeutics Corporate Presentation July 2021 1

Forward Looking Statements This presentation contains forward-looking

statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the "Company") and on information currently available to management. All statements contained in this presentation other than statements of

historical fact are forward-looking statements, including but not limited to statements regarding the expectations and assumptions regarding the future of the Company's business, including its ability to resolve the clinical hold by the FDA

related to CTI-1601, the Company's ability to develop and commercialize CTI-1601 and other planned product candidates, the Company's planned research and development efforts, and other matters regarding the Company's business

strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will,"

"could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project,"

"potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and

other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others,

the Company's ability to successfully engage with the FDA and satisfactorily respond to requests from the FDA for further information and data regarding CTI-1601, the timing and outcome of Larimar's planned interactions with the FDA,

including the clinical hold on CTI-1601, the success, cost and timing of the Company's product development activities, non-clinical studies and clinical trials, including CTI-1601 clinical milestones; that clinical trial results may differ

from final clinical trial results, that earlier non-clinical and clinical data and testing of CTI-1601 may not be predictive of the results or success of clinical trials, and that clinical trial data are subject to differing interpretations and

assessments; the ongoing impact of the COVID-19 pandemic on the Company's clinical trials, manufacturing, regulatory and nonclinical study timelines, ability to raise additional capital and general economic conditions; the Company's

ability to optimize and scale CTI-1601's manufacturing process; the Company's ability to obtain regulatory approval for CTI-1601 and future product candidates; the Company's ability to develop sales and marketing capabilities,

whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; the Company's ability to raise the necessary capital to conduct its product development activities; and other risks

described in the filings made by the Company with the Securities and Exchange Commission (SEC), including but not limited to the Company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current

reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by the Company and its projections of the future, about which it

cannot be certain. As a result, the forward-looking statements may not prove to be accurate. These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements,

except as required by law. 2Forward Looking Statements This presentation contains forward-looking statements that are based on the beliefs and assumptions of Larimar Therapeutics, Inc. (the "Company") and on information currently

available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not limited to statements regarding the expectations and assumptions regarding the future

of the Company's business, including its ability to resolve the clinical hold by the FDA related to CTI-1601, the Company's ability to develop and commercialize CTI-1601 and other planned product candidates, the Company's planned

research and development efforts, and other matters regarding the Company's business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify

forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate,"

"believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all

forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these

forward-looking statements. These risks, uncertainties and other factors include, among others, the Company's ability to successfully engage with the FDA and satisfactorily respond to requests from the FDA for further information and data

regarding CTI-1601, the timing and outcome of Larimar's planned interactions with the FDA, including the clinical hold on CTI-1601, the success, cost and timing of the Company's product development activities, non-clinical studies and

clinical trials, including CTI-1601 clinical milestones; that clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of CTI-1601 may not be predictive of the results or success of

clinical trials, and that clinical trial data are subject to differing interpretations and assessments; the ongoing impact of the COVID-19 pandemic on the Company's clinical trials, manufacturing, regulatory and nonclinical study timelines,

ability to raise additional capital and general economic conditions; the Company's ability to optimize and scale CTI-1601's manufacturing process; the Company's ability to obtain regulatory approval for CTI-1601 and future product

candidates; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; the Company's ability to raise the

necessary capital to conduct its product development activities; and other risks described in the filings made by the Company with the Securities and Exchange Commission (SEC), including but not limited to the Company's periodic reports,

including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. These forward-looking statements are based on a combination of facts and

factors currently known by the Company and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. These forward-looking statements are based on information currently

available to us, and we assume no obligation to update any forward-looking statements, except as required by law. 2

Investment Highlights Clinical-stage biotechnology company with a novel

protein replacement therapy platform Focused on addressing unmet needs in Friedreich's ataxia (FA) and other complex rare diseases based on a platform technology backed by a strong intellectual property portfolio Lead candidate: CTI-1601, a

recombinant fusion protein designed to deliver frataxin to mitochondria Has Orphan Drug (US & EU), Rare Pediatric Disease (US), Fast Track (US) and PRIME (EU) designations for FA Double-blind, placebo-controlled Phase 1 proof-of-concept trials

in FA patients complete Data show dose dependent increases in FXN levels from baseline compared to placebo in all evaluated tissues with daily dosing and that CTI-1601 was generally well tolerated when dosed for up to 13 days -Clinical hold pending

data from an ongoing 180-day NHP study as it relates to initiating additional clinical studies with CTI-1601 Series A investment by Deerfield in Nov. 2016; went public through a reverse merger/PIPE in May 2020 Shareholder base includes high-quality

institutional investors Strong balance sheet ~$81.4 million in cash as of March 31, 2021, with projected runway through the end of 2022 -Raised ~$20 million in gross proceeds in a June ATM transaction of ~ 2.3 million shares 3 FXN:

FrataxinInvestment Highlights Clinical-stage biotechnology company with a novel protein replacement therapy platform Focused on addressing unmet needs in Friedreich's ataxia (FA) and other complex rare diseases based on a platform technology backed

by a strong intellectual property portfolio Lead candidate: CTI-1601, a recombinant fusion protein designed to deliver frataxin to mitochondria Has Orphan Drug (US & EU), Rare Pediatric Disease (US), Fast Track (US) and PRIME (EU) designations

for FA Double-blind, placebo-controlled Phase 1 proof-of-concept trials in FA patients complete Data show dose dependent increases in FXN levels from baseline compared to placebo in all evaluated tissues with daily dosing and that CTI-1601 was

generally well tolerated when dosed for up to 13 days -Clinical hold pending data from an ongoing 180-day NHP study as it relates to initiating additional clinical studies with CTI-1601 Series A investment by Deerfield in Nov. 2016; went public

through a reverse merger/PIPE in May 2020 Shareholder base includes high-quality institutional investors Strong balance sheet ~$81.4 million in cash as of March 31, 2021, with projected runway through the end of 2022 -Raised ~$20 million in gross

proceeds in a June ATM transaction of ~ 2.3 million shares 3 FXN: Frataxin

CTI-1601 is Designed to Deliver Additional Frataxin (FXN) CTI-1601

Maintains the Cleavage Site Between the MTS and Mature Human FXN STRUCTURE OF CTI-1601 STRUCTURE OF ENDOGENOUS FXN Mitochondrial Targeting Mature Mitochondrial Targeting Mature Sequence (MTS) Human FXN Sequence (MTS) Human FXN Cleavage by

mitochondrial processing Cell Cleavage by mitochondrial processing peptidase (MPP) at this site produces Penetrating peptidase (MPP) at this site produces mature human FXN in mitochondria Peptide (CPP) mature human FXN in mitochondria The

maintenance of the cleavage site allows the CPP and MTS to be removed by mitochondrial processing peptidase to produce mature human FXN in the mitochondria 4CTI-1601 is Designed to Deliver Additional Frataxin (FXN) CTI-1601 Maintains the Cleavage

Site Between the MTS and Mature Human FXN STRUCTURE OF CTI-1601 STRUCTURE OF ENDOGENOUS FXN Mitochondrial Targeting Mature Mitochondrial Targeting Mature Sequence (MTS) Human FXN Sequence (MTS) Human FXN Cleavage by mitochondrial processing Cell

Cleavage by mitochondrial processing peptidase (MPP) at this site produces Penetrating peptidase (MPP) at this site produces mature human FXN in mitochondria Peptide (CPP) mature human FXN in mitochondria The maintenance of the cleavage site allows

the CPP and MTS to be removed by mitochondrial processing peptidase to produce mature human FXN in the mitochondria 4

Platform Technology is Supported by a Strong IP Portfolio Pending

CTI-1601 patent application, if issued, extends IP into 2040 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 TAT-MTS-FXN Composition of Matter (broad coverage of CTI-1601) Expiration US 9,045,552 (Exclusive license from Wake Forest) October 2024

Methods of treating FA using TAT-MTS-FXN and delivering TAT-MTS-FXN Expiration CTI-1601 to mitochondria (broad coverage of CTI-1601) December 2025 US 8,735,341 (Exclusive license from Wake Forest) (including Patent Term Adjustment) Patents /

Applications CTI-1601 Composition of Matter and Methods of Treatment Est. Expiration (specific coverage of CTI-1601) July 2040 US/PCT applications pending (Exclusive license from Indiana University) Will be filed in foreign jurisdictions accordingly

Platform Technology*: Molecules for Protein Delivery Est. Expiration Platform US/PCT applications pending March 2041 Applications Will be filed in foreign jurisdictions accordingly *Additional pending applications for platform disease targets

Additional CTI-1601 IP protection CTI-1601 pending applications cover key biomarkers, analytical tools and quantification methods CTI-1601 is eligible for 12 years of market exclusivity upon approval in the US (independent of

patents) and at least 10 years of market exclusivity upon approval in Europe (independent of patents) Granted Pending 5Platform Technology is Supported by a Strong IP Portfolio Pending CTI-1601 patent application, if issued, extends IP into 2040

2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 TAT-MTS-FXN Composition of Matter (broad coverage of CTI-1601) Expiration US 9,045,552 (Exclusive license from Wake Forest) October 2024 Methods of treating FA using TAT-MTS-FXN and delivering

TAT-MTS-FXN Expiration CTI-1601 to mitochondria (broad coverage of CTI-1601) December 2025 US 8,735,341 (Exclusive license from Wake Forest) (including Patent Term Adjustment) Patents / Applications CTI-1601 Composition of Matter and Methods of

Treatment Est. Expiration (specific coverage of CTI-1601) July 2040 US/PCT applications pending (Exclusive license from Indiana University) Will be filed in foreign jurisdictions accordingly Platform Technology*: Molecules for Protein Delivery Est.

Expiration Platform US/PCT applications pending March 2041 Applications Will be filed in foreign jurisdictions accordingly *Additional pending applications for platform disease targets Additional CTI-1601 IP protection CTI-1601 pending

applications cover key biomarkers, analytical tools and quantification methods CTI-1601 is eligible for 12 years of market exclusivity upon approval in the US (independent of patents) and at least 10 years of market exclusivity upon approval

in Europe (independent of patents) Granted Pending 5

Friedreich's Ataxia (FA) Rare and Progressive Disease Caused by

genetic defect resulting in low levels of frataxin Patients with FA only produce ~20-40% of normal frataxin levels depending 1 on the tissue, sampling technique, and assay considered Affects ~5,000 patients in the U.S. & ~20,000

patients in the EU >70% of patients present before age 14 Initial symptoms may include unsteady posture, frequent falling and progressive difficulty in walking By the time symptoms occur, heart damage may have already occurred

Progressive disease: Symptoms worsen and patients are eventually confined to a wheelchair with speech becoming hesitant and jerky (often referred to as "scanning of speech") Life expectancy of 30-50 years Early death

usually caused by heart disease No approved therapies available Current treatment options are limited to symptom management 6 6 1. E.C. Deutsch et al. Molecular Genetics and Metabolism 101 (2010) 238-245Friedreich's Ataxia (FA)

Rare and Progressive Disease Caused by genetic defect resulting in low levels of frataxin Patients with FA only produce ~20-40% of normal frataxin levels depending 1 on the tissue, sampling technique, and assay considered Affects

~5,000 patients in the U.S. & ~20,000 patients in the EU >70% of patients present before age 14 Initial symptoms may include unsteady posture, frequent falling and progressive difficulty in walking By the time symptoms occur,

heart damage may have already occurred Progressive disease: Symptoms worsen and patients are eventually confined to a wheelchair with speech becoming hesitant and jerky (often referred to as "scanning of speech") Life expectancy

of 30-50 years Early death usually caused by heart disease No approved therapies available Current treatment options are limited to symptom management 6 6 1. E.C. Deutsch et al. Molecular Genetics and Metabolism 101 (2010)

Strong Relationship with FARA Company has strong relationship with

Friedreich's Ataxia Research Alliance (FARA) National, non-profit organization dedicated to the pursuit of scientific research leading to treatments and a cure for FA FARA provides industry with several key items Assistance

with patient recruitment and education Access to Global Patient Registry with demographic and clinical information on more than 1,000 FA patients Sponsored a Patient-Focused Drug Development Meeting in 2017 resulting in a publication

titled "The Voice of the Patient" 7Strong Relationship with FARA Company has strong relationship with Friedreich's Ataxia Research Alliance (FARA) National, non-profit organization dedicated to the pursuit of scientific

research leading to treatments and a cure for FA FARA provides industry with several key items Assistance with patient recruitment and education Access to Global Patient Registry with demographic and clinical information on more than

1,000 FA patients Sponsored a Patient-Focused Drug Development Meeting in 2017 resulting in a publication titled "The Voice of the Patient" 7

Executive Summary of Phase 1 POC Data CTI-1601 appears to be generally

well tolerated at doses up to 100 mg Safety administered daily for 13 days Daily dosing of CTI-1601 resulted in dose-dependent increases in FXN levels from Pharmacodynamics baseline compared to placebo controls in all evaluated tissues

Pharmacokinetics Pharmacokinetic analyses support evaluating a once-daily dosing regimen for CTI-1601 Daily subcutaneous (SC) administration of 50mg and 100mg doses of CTI-1601 resulted in FXN levels in buccal cells that are at, or in excess of,

those we would Conclusion expect to see in phenotypically normal heterozygous carriers (who have FXN levels of ~50% of unaffected persons) 8 8 POC: Proof-of-conceptExecutive Summary of Phase 1 POC Data CTI-1601 appears to be generally well tolerated

at doses up to 100 mg Safety administered daily for 13 days Daily dosing of CTI-1601 resulted in dose-dependent increases in FXN levels from Pharmacodynamics baseline compared to placebo controls in all evaluated tissues Pharmacokinetics

Pharmacokinetic analyses support evaluating a once-daily dosing regimen for CTI-1601 Daily subcutaneous (SC) administration of 50mg and 100mg doses of CTI-1601 resulted in FXN levels in buccal cells that are at, or in excess of, those we would

Conclusion expect to see in phenotypically normal heterozygous carriers (who have FXN levels of ~50% of unaffected persons) 8 8 POC: Proof-of-concept

CTI-1601: Phase 1 Clinical Program in Patients with FA Program consisted

of double-blind, placebo controlled single- and multiple-ascending dose trials Phase 1 Development Plan Two double-blind, placebo-controlled dosing trials in patients with FA Patient dosing began December 2019 Safety Review

Committee assessed all blinded data between each cohort to ensure patient safety Number of subjects: 28 Dose levels: 25 mg, 50 mg, 75 mg and 100 mg (subcutaneous administration) Single Ascending Dose Treatment Duration: 1 day 1 Endpoint:

Safety and tolerability (SAD) 2 Endpoints: PK; PD; FXN levels; multiple exploratory Eligible patients Status: Complete with analysis ongoing from SAD trial could enroll in MAD trial Number of Subjects: 27 Dose Range: 25 mg, 50 mg, 100 mg

(subcutaneous administration) Treatment Regimen: Multiple increasing doses administered subcutaneously over 13 days Multiple Ascending Dose 1 Endpoint: Safety and tolerability (MAD) 2 Endpoints: PK; PD; FXN levels (buccal cells,

platelets, optional skin biopsies); multiple exploratory Status: Complete with analysis ongoing 9CTI-1601: Phase 1 Clinical Program in Patients with FA Program consisted of double-blind, placebo controlled single- and multiple-ascending dose trials

Phase 1 Development Plan Two double-blind, placebo-controlled dosing trials in patients with FA Patient dosing began December 2019 Safety Review Committee assessed all blinded data between each cohort to ensure patient safety

Number of subjects: 28 Dose levels: 25 mg, 50 mg, 75 mg and 100 mg (subcutaneous administration) Single Ascending Dose Treatment Duration: 1 day 1 Endpoint: Safety and tolerability (SAD) 2 Endpoints: PK; PD; FXN levels; multiple

exploratory Eligible patients Status: Complete with analysis ongoing from SAD trial could enroll in MAD trial Number of Subjects: 27 Dose Range: 25 mg, 50 mg, 100 mg (subcutaneous administration) Treatment Regimen: Multiple increasing doses

administered subcutaneously over 13 days Multiple Ascending Dose 1 Endpoint: Safety and tolerability (MAD) 2 Endpoints: PK; PD; FXN levels (buccal cells, platelets, optional skin biopsies); multiple exploratory Status: Complete with

MAD Trial Patient Enrollment 16 out of 28 patients who participated in